Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments BAF312 and CJM112 Ofatumumab is a fully human monoclonal antibody for relapsing remitting multiple sclerosis (RRMS) which targets CD20 and … Read the full press release
Posted in Healthcare, Investment, Pharma & Biotech, Switzerland
Tagged Gilenya®, GlaxoSmithKline plc (GSK), multiple sclerosis, Novartis, Ofatumumab
The new RebiSmart® injection device offers many new updates including wireless transmission of injection times and doses MSdialog™software is designed to more effectively engage people with MS and their health care providers with treatment adherence information and health related outcome reports … Read the full press release
Posted in Germany, Healthcare, Internet & Online, Pharma & Biotech, Technology
Tagged M&S, Merck Serono, MSdialog, multiple sclerosis, RebiSmart
16-8-2013 — /EuropaWire/ — Immunologists at LMU have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the … Read the full press release
Posted in Education, Germany, Healthcare, Pharma & Biotech, Science
Tagged autoimmune disease, autoimmune diseases, BMBF, Clinical Neuroimmunology, Cytotoxic T cells, fight tumors, LMU, multiple sclerosis, pathogen-derived protein fragments, peptides, Privatdozent Dr. Klaus Dornmair, Prof. Jörg Prinz, psoriasis, T cells, treat autoimmune diseases, tumor-specific antigens, tumors, Validation of the Innovation Potential of Scientific Research
Princeton, New Jersey, 29-7-2013 — /EuropaWire/ — Sandoz announced today that the US Federal Circuit Court of Appeals has invalidated several patents asserted against the company by Teva Pharmaceuticals in litigation concerning a generic version of Copaxone® – one of the leading … Read the full press release
Cordoba, Spain, 12-6-2013 — /europawire.eu/ — VivaCell Biotechnology España S.L., Cordoba, Spain today announced that it has entered into joint Research Collaboration and Commercialization Agreements with Aphios Corporation, USA, to develop therapeutics for multiple sclerosis and other neurodegenerative diseases of the central … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Spain
Tagged Aphios Corporation, biotech company, biotech development, biotech pharma companies, biotechnology, cannabinoid receptor, cannabinoids, central nervous system, CNS and neurological disorders, Cordoba, endocannabinoid system, multiple sclerosis, neurodegenerative diseases, novel class of compounds, therapeutics for multiple sclerosis, VivaCell Biotechnology, VivaCell Biotechnology España S.L.
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?